Skip to main content
. 2020 May 15;26:e923867-1–e923867-18. doi: 10.12659/MSM.923867

Supplementary Table 2.

Univariable Cox regression for analyzing the prognostic factors for gastric cancer patients with distant metastases.

Subject characteristics M-Met Liver-Met Lung-Met Bone-Met Brain-Met
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age
 <65 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 ≥65 1.31 (1.26–1.36) <0.001 1.34 (1.26–1.42) <0.001 1.17 (1.06–1.29) 0.001 1.12 (1.01–1.24) 0.036 1.14 (0.87–1.49) 0.355
Gender
 Male 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Female 0.98 (0.94–1.02) 0.333 0.95 (0.89–1.01) 0.116 1.02 (0.92–1.13) 0.702 1.04 (0.94–1.17) 0.442 1.02 (0.75–1.38) 0.894
Race
 White 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Black 0.99 (0.93–1.04) 0.597 0.95 (0.88–1.02) 0.166 1.12 (0.97–1.30) 0.135 1.16 (0.98–1.37) 0.084 1.16 (0.72–1.87) 0.540
 Others 0.99 (0.94–1.05) 0.746 0.99 (0.91–1.09) 0.850 1.14 (0.98–1.32) 0.950 1.06 (0.91–1.24) 0.460 1.29 (0.81–2.05) 0.290
Marital status
 Married 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Unmarried 1.18 (1.13–1.23) <0.001 1.15 (1.09–1.22) <0.001 1.21 (1.10–1.34) <0.001 1.13 (1.02–1.26) 0.025 1.03 (0.78–1.38) 0.825
Insurance status
 Insured 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Uninsured 1.05 (0.96–1.14) 0.303 1.14 (0.99–1.30) 0.067 1.07 (0.85–1.35) 0.562 1.08 (0.84–1.38) 0.548 1.54 (0.86–2.78) 0.148
Primary site
 Proximal third 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Mid 1.06 (0.99–1.14) 0.084 1.04 (0.93–1.15) 0.495 1.18 (0.97–1.43) 0.100 1.29 (1.08–1.55) 0.006 1.69 (0.89–3.23) 0.112
 Distal third 1.02 (0.97–1.08) 0.488 1.04 (0.96–1.14) 0.328 1.18 (1.01–1.38) 0.043 1.32 (1.10–1.57) 0.002 1.43 (0.81–2.54) 0.222
 Stomach, NOS 1.06 (1.01–1.11) 0.017 1.00 (0.93–1.07) 0.983 1.19 (1.06–1.34) 0.003 1.18 (1.04–1.33) 0.010 1.44 (1.06–1.96) 0.021
 Overlapping 1.17 (1.09–1.26) <0.001 1.29 (1.15–1.44) <0.001 1.32 (1.08–1.60) 0.006 1.17 (0.95–1.46) 0.147 0.97 (0.40–2.37) 0.944
Histology
 Adenoca-rcinoma 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Mucous carcinoma 1.02 (0.88–1.17) 0.845 1.43 (1.11–1.85) 0.005 1.00 (0.70–1.42) 0.995 0.73 (0.47–1.14) 0.163 0.95 (0.24–3.85) 0.944
 Signet-ring cell carcinoma 1.06 (1.01–1.11) 0.018 1.17 (1.04–1.31) 0.007 1.13 (0.99–1.30) 0.080 1.01 (0.90–1.14) 0.831 1.35 (0.95–1.92) 0.099
 Unknown 0.67 (0.63–0.71) <0.001 0.63 (0.58–0.69) <0.001 1.07 (0.92–1.26) 0.372 1.07 (0.88–1.29) 0.502 1.11 (0.70–1.77) 0.665
Grade
 I 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 II 1.51 (1.30–1.77) <0.001 1.57 (1.28–1.92) <0.001 1.24 (0.89–1.73) 0.204 0.74 (0.44–1.24) 0.251 NA NA
 III 1.83 (1.57–2.12) <0.001 2.02 (1.66–2.47) <0.001 1.65 (1.20–2.28) 0.002 0.95 (0.58–1.55) 0.825 NA NA
 IV 1.34 (1.09–1.65) 0.005 1.46 (1.11–1.92) 0.008 1.12 (0.65–0.94) 0.691 0.88 (0.46–1.70) 0.700 NA NA
T stage
 T1 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 T2 0.71 (0.64–0.78) <0.001 0.59 (0.50–0.70) <0.001 0.90 (0.68–1.20) 0.456 0.58 (0.43–0.80) 0.001 1.30 (0.62–2.72) 0.486
 T3 0.71 (0.66–0.76) <0.001 0.68 (0.61–0.75) <0.001 0.90 (0.75–1.07) 0.225 0.83 (0.69–1.01) 0.059 0.85 (0.50–1.46) 0.561
 T4 0.92 (0.86–0.97) 0.004 0.91 (0.83–1.00) 0.043 1.18 (1.01–1.38) 0.042 1.01 (0.84–1.22) 0.932 1.72 (1.02–2.91) 0.043
N stage
 N0 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 N1 1.01 (0.97–1.06) 0.572 1.09 (1.02–1.16) 0.012 0.98 (0.88–1.10) 0.758 1.09 (0.97–1.23) 0.155 1.20 (0.87–1.67) 0.271
 N2 0.84 (0.77–0.92) <0.001 0.99 (0.86–1.13) 0.867 0.96 (0.75–1.24) 0.745 0.93 (0.71–1.21) 0.571 0.86 (0.43–1.73) 0.676
 N3 0.86 (0.79–0.93) <0.001 1.01 (0.87–1.17) 0.944 1.11 (0.86–1.44) 0.410 0.95 (0.72–1.24) 0.686 1.32 (0.71–2.44) 0.383
Surgery
 No 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Yes 0.51 (0.48–0.55) <0.001 0.51 (0.46–0.57) <0.001 0.73 (0.57–0.92) 0.009 0.66 (0.50–0.87) 0.003 0.48 (0.25–0.91) 0.025
Radiation
 No/unknown 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Yes 0.91 (0.87–0.96) 0.001 1.01 (0.93–1.09) 0.845 0.80 (0.71–0.91) <0.001 0.89 (0.79–0.99) 0.036 0.67 (0.51–0.89) 0.005
Chemotherapy
 No/unknown 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Yes 0.37 (0.36–0.39) <0.001 0.37 (0.34–0.39) <0.001 0.36 (0.32–0.40) <0.001 0.38 (0.34–0.42) <0.001 0.41 (0.31–0.55) <0.001
Number of mets
 ≤1 1.00 (Reference) 1.00
 >1 1.44 (1.37–1.53) <0.001
Other mets
 No 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00 1.00 (Reference) 1.00
 Yes 1.41 (1.32–1.50) <0.001 1.27 (1.15–1.40) <0.001 1.01 (0.91–1.12) 0.813 1.34 (1.01–1.78) 0.040

Met – metastases; HR – hazard ratio; CI – confidence interval; NOS – not otherwise specified; NA – not available.